Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs Limited has reaffirmed its financial guidance for FY25, maintaining its revenue projection between $725 million and $752 million, and underlying EBIT between $65 million and $73 million. The company has consistently aligned its guidance with market expectations, as confirmed by sell-side analyst reports, and does not anticipate any material impact on its share price from its recent half-year results announcement.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, focusing on providing pathology services. The company is based in Australia and is involved in offering diagnostic services to support healthcare providers and patients.
YTD Price Performance: -4.94%
Average Trading Volume: 552,442
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$655.9M
See more insights into ACL stock on TipRanks’ Stock Analysis page.